dc.contributor.author | Luna Tapia, Arturo | spa |
dc.contributor.author | Kerns, Morgan E. | spa |
dc.contributor.author | Jursic, Branko S. | spa |
dc.contributor.author | Eberle, Karen E. | spa |
dc.contributor.author | Palmer, Glen E. | spa |
dc.coverage.spatial | Colombia | spa |
dc.date.accessioned | 2019-10-02T16:38:52Z | spa |
dc.date.available | 2019-10-02T16:38:52Z | spa |
dc.date.issued | 2019-10-02 | spa |
dc.identifier.citation | Luna, A., Kerns, M.E., Eberle, K.E., Jursic, B.S. & Palmer, G.E. (2015). Trafficking through the late endosome significantly impacts candida albicans tolerance of the azole antifungals. Antimicrobial Agents and Chemotherapy . 59(4), 2410 – 2420. | spa |
dc.identifier.issn | 1535-9786 | spa |
dc.identifier.uri | https://repositorio.unisucre.edu.co/handle/001/817 | spa |
dc.description | Artículo digital. | spa |
dc.description.abstract | The purpose of this study was to characterize the effects of azole treatment upon the integrity of the Candida albicans vacuole and to determine whether, in turn, vacuolar trafficking influences azole susceptibility. Profound fragmentation of the C. albicans vacuole can be observed as an early consequence of azole treatment, and it precedes significant growth inhibition. In addition, a C. albicans vps21/ mutant, blocked in membrane trafficking through the late endosomal prevacuolar compartment (PVC), is able to grow significantly more than the wild type in the presence of several azole antifungals under standard susceptibility testing conditions. F. | eng |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Estados Unidos: Antimicrobial Agents and Chemotherapy , 2015. | spa |
dc.relation.ispartof | Revista | spa |
dc.rights | Derechos Reservados - Universidad de Sucre, 2019 | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | spa |
dc.source | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356793/pdf/zac2410.pdf. | spa |
dc.title | Trafficking through the late endosome significantly impacts candida albicans tolerance of the azole antifungals. | spa |
dc.type | Artículo de revista | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.type.driver | info:eu-repo/semantics/article | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | spa |
dc.identifier.doi | 10.1128/AAC.04239-14 | spa |
dc.relation.references | Vandeputte P, Ferrari S, Coste AT. 2012. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012:713687. http: //dx.doi.org/10.1155/2012/713687. | spa |
dc.relation.references | Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten WH, Borgers M, Ramaekers F, Odds FC, Bossche HV. 1999. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701– 2713. | spa |
dc.relation.references | Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676 –2684. http://dx.doi.org/10.1128/AAC.45.10.2676 -2684.2001. | spa |
dc.relation.references | White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41:1482–1487. | spa |
dc.relation.references | Sanglard D, Ischer F, Monod M, Bille J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143:405–416. http://dx.doi.org/10.1099/00221287-143-2-405. | spa |
dc.rights.creativecommons | Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) | spa |
dc.subject.proposal | Candida albicans | spa |
dc.subject.proposal | Antifungals | spa |
dc.subject.proposal | Azole | spa |
dc.contributor.corporatename | American Society for Microbiology. | spa |
dc.type.content | Text | spa |
dc.type.redcol | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |